Essais liés9clinical trials
VilleShanghailocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06875310

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
Domvanalimab Cancer Phase 2 NCT06727565 VELOCITY-HNSCC — Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 ACTIVE_NOT_RECRUITING
Rimegepant Migraine Phase 3 NCT05810038 A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects. COMPLETED
Amivantamab Cancer Phase 3 NCT04538664 PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions ACTIVE_NOT_RECRUITING
Vicadrostat Hypertension Phase 3 NCT07064473 EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease RECRUITING
Galcanezumab Migraine Phase 3 NCT03963232 PERSIST — A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine COMPLETED
ASP1570 Cancer Phase 1 NCT05083481 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors TERMINATED
Adagrasib Cancer Phase 3 NCT06875310 A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) RECRUITING
Rimegepant Migraine Phase 3 NCT06641466 A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine RECRUITING
Donanemab Alzheimer Phase 3 NCT07571161 Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease RECRUITING